Alivus Q2 FY27 net profit rises 51% on 16% revenue growth

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1392.00

prior close

₹1451.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.8%+1.7% vs sector

On the reaction day the stock moved 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+1.5

15m

+1.5

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9pendingpending-0.8+1.7

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved Alivus Life Sciences' unaudited results for the quarter and half year ended September 2026. Q2 revenue rose 16 percent year on year to Rs 681.99 crore, while net profit rose 51 percent to Rs 196.75 crore. For the half year, revenue rose 11 percent to Rs 1,322.40 crore and net profit rose 42 percent to Rs 356.82 crore. Cash from operations was Rs 459.69 crore.

Likely market impact

Strong profit growth and positive cash flow may support the share price, but the response will depend on valuation and the company outlook.